LLY

Eli Lilly & Co. 10-Q Summary: Quarter Ended September 30, 2005

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2005, and the nine-month period ended on that date. Eli Lilly and Company operates primarily in the pharmaceutical products segment, with a smaller animal health segment included in the same reporting category. The company is headquartered in Indianapolis, Indiana.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 10% in Q3 2005 and 5% for the nine-month period compared to 2004. Growth was driven by new products (Cymbalta, Alimta, Forteo) and strong international sales, partially offset by declines in Zyprexa, Strattera, and Prozac sales in the U.S.
• Profitability Decline (YTD): While Q3 net income rose 5%, nine-month net income fell 29% to $1.28 billion. This decline is primarily attributed to a $1.07 billion pre-tax charge for product liability matters (Zyprexa litigation) recorded in Q2 2005 and increased stock-based compensation expenses due to the adoption of SFAS 123(R).
• Expense Increases: Research and development expenses rose 15% in Q3 and 12% YTD. Marketing and administrative expenses increased 13% in Q3 and 4% YTD, driven by incentive compensation and the new accounting standard for stock options.
• Product Liability Charge: A significant non-recurring charge of $1.07 billion was recorded in Q2 2005, including a $700 million settlement fund for Zyprexa claims and reserves for future claims. This reduced earnings per share by $0.90 for the nine-month period.

Guidance, Outlook, and Risks

• 2005 Guidance: Management expects full-year 2005 earnings per share to be in the range of $1.90 to $1.96, inclusive of the $0.90 per share product liability charge and incremental equity compensation expenses. Q4 2005 EPS is expected to be between $0.73 and $0.79.
• Legal Contingencies:
  • Zyprexa Litigation: The company entered a master settlement agreement covering approximately 70% of U.S. product liability claims ($690 million fund + $10 million admin). However, litigation continues for remaining claims, and the company faces ongoing government investigations regarding marketing practices for Zyprexa, Prozac, and other products.
  • Patent Challenges: Generic manufacturers have challenged patents for Zyprexa (expiring 2011) and Evista. While a district court ruled in Lilly's favor on Zyprexa patents in April 2005, the decision is under appeal.
• Accounting Changes: The adoption of SFAS 123(R) in 2005 requires expensing stock options, reducing reported net income compared to prior periods where no expense was recognized for options.
• Liquidity: The company maintains strong liquidity with $6.23 billion in cash and short-term investments. It expects to repay approximately $1.5 billion of debt by the end of 2006.

Key Facts for Investor Verification

• Verify the status of the Zyprexa settlement agreement and the number of claimants required to release the company (minimum 7,193) to finalize the $700 million fund.
• Monitor the outcome of the appealed Zyprexa patent litigation, as an unfavorable ruling could materially impact future revenue.
• Track the progress of government investigations into marketing practices for Zyprexa, Prozac, and rebate agreements, which could result in fines or penalties.
• Assess the impact of wholesaler destocking (estimated $170 million in the first nine months) on reported sales figures versus underlying demand.
• Review the company's ability to meet its 2005 EPS guidance given the volatility in litigation costs and the ongoing transition to new accounting standards for stock compensation.